Terms: = Leukemia AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB
695 results:
1. Novel guanidine derivatives targeting leukemia as selective Src/Abl dual inhibitors: Design, synthesis and anti-proliferative activity.
Moustafa AH; AboulMagd AM; Ali AM; Khodairy A; Marzouk AA; Nafady A; T M Nemr M
Bioorg Chem; 2024 Jun; 147():107410. PubMed ID: 38688197
[TBL] [Abstract] [Full Text] [Related]
2. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
[TBL] [Abstract] [Full Text] [Related]
3. BCL-X
Jenkins LJ; Luk IY; Chionh F; Tan T; Needham K; Ayton J; Reehorst CM; Vukelic N; Sieber OM; Mouradov D; Gibbs P; Williams DS; Tebbutt NC; Desai J; Hollande F; Dhillon AS; Lee EF; Merino D; Fairlie WD; Mariadason JM
Cell Death Dis; 2024 Mar; 15(3):183. PubMed ID: 38429301
[TBL] [Abstract] [Full Text] [Related]
4. Pharmaco-phosphoproteomic analysis of cancer-associated KIT mutations D816V and V560G.
Murray HC; Miller K; Dun MD; Verrills NM
Proteomics; 2024 May; 24(9):e2300309. PubMed ID: 38334196
[TBL] [Abstract] [Full Text] [Related]
5. [Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia].
Dou XL; Liu RX; Liu Y; Peng N; Wen L; Wu Y; Li Q; Zhong YP; Zhou X; Liao AJ; Jiang HN; Ma XJ; Dong HH; Fan SJ; Zhao YQ; Hu DH; Lu J
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):499-506. PubMed ID: 38317361
[No Abstract] [Full Text] [Related]
6. Effect of Tyrosine Kinase Inhibitor Therapy on Estimated Glomerular Filtration Rate in Patients with Chronic Myeloid leukemia.
Sönmez Ö; Özgür Yurttaş N; İhtiyaroğlu İ; Çakır HM; Atlı Z; Elverdi T; Salihoğlu A; Seyahi N; Ar MC; Öngören Ş; Başlar Z; Soysal T; Eşkazan AE
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):232-239. PubMed ID: 38281820
[TBL] [Abstract] [Full Text] [Related]
7. Benzimidazole-Based Derivatives as Apoptotic Antiproliferative Agents: Design, Synthesis, Docking, and Mechanistic Studies.
Youssif BGM; Morcoss MM; Bräse S; Abdel-Aziz M; Abdel-Rahman HM; Abou El-Ella DA; Abdelhafez ESMN
Molecules; 2024 Jan; 29(2):. PubMed ID: 38257358
[TBL] [Abstract] [Full Text] [Related]
8. Exploring Thiazolopyridine AV25R: Unraveling of Biological Activities, Selective Anti-Cancer Properties and In Silico Target and Binding Prediction in Hematological Neoplasms.
Ladwig A; Gupta S; Ehlers P; Sekora A; Alammar M; Koczan D; Wolkenhauer O; Junghanss C; Langer P; Murua Escobar H
Molecules; 2023 Dec; 28(24):. PubMed ID: 38138609
[TBL] [Abstract] [Full Text] [Related]
9. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
Lu X; Yu R; Li Z; Yang M; Dai J; Liu M
Cancer Lett; 2024 Feb; 582():216517. PubMed ID: 38101609
[TBL] [Abstract] [Full Text] [Related]
10. Osimertinib Covalently Binds to CD34 and Eliminates Myeloid leukemia Stem/Progenitor Cells.
Xia L; Liu JY; Yang MY; Zhang XH; Jiang Y; Yin QQ; Luo CH; Liu HC; Kang ZJ; Zhang CT; Gao BB; Zhou AW; Cai HY; Waller EK; Yan JS; Lu Y
Cancer Res; 2024 Feb; 84(3):479-492. PubMed ID: 38095536
[TBL] [Abstract] [Full Text] [Related]
11. erbb4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
[TBL] [Abstract] [Full Text] [Related]
12. Associations between BMI in youth and site-specific cancer in men-A cohort study with register linkage.
Onerup A; Mehlig K; Af Geijerstam A; Ekblom-Bak E; Kuhn HG; Lissner L; Rosengren A; Börjesson M; Åberg M
Obesity (Silver Spring); 2024 Feb; 32(2):376-389. PubMed ID: 37927128
[TBL] [Abstract] [Full Text] [Related]
13. The prevalence of anemia in people with chronic kidney disease after hematopoietic stem cell transplantation.
Kępska-Dzilińska M; Karakulska-Prystupiuk E; Kaszyńska A; Basak GW; Małyszko J
Ren Fail; 2023; 45(2):2263581. PubMed ID: 37782282
[TBL] [Abstract] [Full Text] [Related]
14. Development and Assessment of 1,5-Diarylpyrazole/Oxime Hybrids Targeting egfr and JNK-2 as Antiproliferative Agents: A Comprehensive Study through Synthesis, Molecular Docking, and Evaluation.
Abdelrahman KS; Hassan HA; Abdel-Aziz SA; Marzouk AA; Shams R; Osawa K; Abdel-Aziz M; Konno H
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764297
[TBL] [Abstract] [Full Text] [Related]
15. Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations.
More P; Ngaffo JAM; Goedtel-Armbrust U; Hähnel PS; Hartwig UF; Kindler T; Wojnowski L
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629110
[TBL] [Abstract] [Full Text] [Related]
16. The design, synthesis, biological evaluation, and molecular docking of new 5-aminosalicylamide-4-thiazolinone hybrids as anticancer agents.
Othman SA; Abou-Ghadir OF; Ramadan WS; Mostafa YA; El-Awady R; Abdu-Allah HHM
Arch Pharm (Weinheim); 2023 Oct; 356(10):e2300315. PubMed ID: 37551741
[TBL] [Abstract] [Full Text] [Related]
17. Cytotoxic activity of quinolinequinones in cancer: In vitro studies, molecular docking, and ADME/PK profiling.
Jannuzzi AT; Yilmaz Goler AM; Shilkar D; Mondal S; Basavanakatti VN; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biol Drug Des; 2023 Nov; 102(5):1133-1154. PubMed ID: 37537000
[TBL] [Abstract] [Full Text] [Related]
18. Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through egfr/AKT and Wnt/β-catenin signaling.
Tang Z; Yang Y; Chen W; Liang T
Hepatol Commun; 2023 Aug; 7(8):. PubMed ID: 37486965
[TBL] [Abstract] [Full Text] [Related]
19. Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States.
Roskoski R
Pharmacol Res; 2023 Aug; 194():106847. PubMed ID: 37454916
[TBL] [Abstract] [Full Text] [Related]
20. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.
Huo Q; Lv J; Zhang J; Huang H; Hu H; Zhao Y; Zhang X; Wang Y; Zhou Y; Qiu J; Ye Y; Huang A; Chen Y; Qin L; Qin D; Li P; Cai G
Cytotherapy; 2023 Oct; 25(10):1037-1047. PubMed ID: 37436338
[TBL] [Abstract] [Full Text] [Related]
[Next]
